Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Affitope PD01

Next Previous
X
Search
Drug Profile

Affitope PD01

Alternative Names: ACI-7104; ACI-7104.056; Affitope-PD01A; anti-a-syn vaccine; Parkinson's disease vaccine - AFFiRiS; PD 01; PD-01A

Latest Information Update: 22 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AFFiRiS
  • Developer AC Immune; AFFiRiS
  • Class Antiparkinsonians; Peptide vaccines
  • Mechanism of Action Alpha-synuclein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Parkinson's disease
  • No development reported Multiple system atrophy

Most Recent Events

  • 14 Nov 2024 Efficacy and adverse events data from a phase II clinical trials in Parkinson's disease released by AC Immune
  • 31 Dec 2023 AC Immune has pending patent applications for affitope PD01 in multiple countries
  • 31 Dec 2023 AC Immune owns issued patents for affitope PD01 in multiple countries including USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top